P Halfon

Summary

Affiliation: Alphabio Laboratory
Country: France

Publications

  1. ncbi Detection of IL28B SNP DNA from buccal epithelial cells, small amounts of serum, and dried blood spots
    Philippe Halfon
    Laboratoire Alphabio, Hopital Ambroise Pare, Marseille, France
    PLoS ONE 7:e33000. 2012
  2. ncbi Meta-analyses of FibroTest diagnostic value in chronic liver disease
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    BMC Gastroenterol 7:40. 2007
  3. ncbi Slow viral dynamics of hepatitis C virus genotype 4
    P Halfon
    Alphabio Laboratory, Virological Department, Marseille, France
    J Viral Hepat 10:351-3. 2003
  4. ncbi Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients
    P Halfon
    Laboratoire Alphabio, Marseille, France
    Aliment Pharmacol Ther 30:61-70. 2009
  5. ncbi FibroTest-ActiTest as a non-invasive marker of liver fibrosis
    Philippe Halfon
    Laboratoire Alphabio, Maladies Infectieuses, Hôpital Ambroise Paré Marseille, France
    Gastroenterol Clin Biol 32:22-39. 2008
  6. ncbi Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response
    Philippe Halfon
    Virological Department, Alphabio Laboratory, Marseille, France
    Eur J Gastroenterol Hepatol 15:1067-71. 2003
  7. ncbi Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay
    Philippe Halfon
    Laboratoire Alphabio, 23 Rue de Friedland, Hopital Ambroise Pare, 13006 Marseille, France
    J Clin Microbiol 46:2106-8. 2008
  8. ncbi [Noninvasive methods for predicting liver fibrosis in patients with chronic hepatitis C: alternatives to liver biopsy]
    Philippe Halfon
    Laboratoire Alphabio, Marseille
    Presse Med 36:457-66. 2007
  9. ncbi Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C
    Philippe Halfon
    Laboratoire Alphabio, 23 rue Friedland, 13006 Marseille, France
    J Hepatol 46:395-402. 2007
  10. ncbi Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance
    Philippe Halfon
    Alphabio Laboratory, 23 Rue de Friedland, 13006 Marseille, France
    J Clin Microbiol 45:313-6. 2007

Collaborators

Detail Information

Publications79

  1. ncbi Detection of IL28B SNP DNA from buccal epithelial cells, small amounts of serum, and dried blood spots
    Philippe Halfon
    Laboratoire Alphabio, Hopital Ambroise Pare, Marseille, France
    PLoS ONE 7:e33000. 2012
    ..The aim of the study was to investigate the reliability and accuracy of alternative routes of testing for single nucleotide polymorphism allele rs12979860CC...
  2. ncbi Meta-analyses of FibroTest diagnostic value in chronic liver disease
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    BMC Gastroenterol 7:40. 2007
    ....
  3. ncbi Slow viral dynamics of hepatitis C virus genotype 4
    P Halfon
    Alphabio Laboratory, Virological Department, Marseille, France
    J Viral Hepat 10:351-3. 2003
    ..The viral dynamics parameters of HCV-4 appear similar to those of HCV-1 and slower than those of HCV-2. HCV-4 infected patients should be grouped with those with HCV-1 when therapeutic schemes are considered in relation to genotype...
  4. ncbi Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients
    P Halfon
    Laboratoire Alphabio, Marseille, France
    Aliment Pharmacol Ther 30:61-70. 2009
    ..Few data have reported the influence of IR on steatosis and fibrosis in the context of HIV-HCV coinfection...
  5. ncbi FibroTest-ActiTest as a non-invasive marker of liver fibrosis
    Philippe Halfon
    Laboratoire Alphabio, Maladies Infectieuses, Hôpital Ambroise Paré Marseille, France
    Gastroenterol Clin Biol 32:22-39. 2008
    ..Indeed, the prognostic performance of FibroTest was at least as accurate as that of biopsy in patients with chronic hepatitis C or B, or ALD...
  6. ncbi Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response
    Philippe Halfon
    Virological Department, Alphabio Laboratory, Marseille, France
    Eur J Gastroenterol Hepatol 15:1067-71. 2003
    ..The aim of the study was to analyse viral kinetics during the first 6 weeks of treatment (interferon plus ribavirin) in 18 relapsed hepatitis C patients after a first course of interferon monotherapy...
  7. ncbi Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay
    Philippe Halfon
    Laboratoire Alphabio, 23 Rue de Friedland, Hopital Ambroise Pare, 13006 Marseille, France
    J Clin Microbiol 46:2106-8. 2008
    ..The significance of such occult infection must be elucidated...
  8. ncbi [Noninvasive methods for predicting liver fibrosis in patients with chronic hepatitis C: alternatives to liver biopsy]
    Philippe Halfon
    Laboratoire Alphabio, Marseille
    Presse Med 36:457-66. 2007
    ....
  9. ncbi Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C
    Philippe Halfon
    Laboratoire Alphabio, 23 rue Friedland, 13006 Marseille, France
    J Hepatol 46:395-402. 2007
    ..We evaluated the test performance profile (TPP) of blood tests of liver fibrosis...
  10. ncbi Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance
    Philippe Halfon
    Alphabio Laboratory, 23 Rue de Friedland, 13006 Marseille, France
    J Clin Microbiol 45:313-6. 2007
    ..The NPV was 97.4% for the AMPLICOR assay and might be compromised if HPV types 26, 53, and 66 were considered oncogenic. The accuracy of these two assays is good and is compatible with routine clinical use in the triage of ASCUS cases...
  11. ncbi Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection
    Philippe Halfon
    Alphabio Laboratory, 23 Rue de Friedland, 13006 Marseille, France
    J Clin Microbiol 44:2507-11. 2006
    ..In conclusion, the high sensitivities and large dynamic ranges of the Abbott and Roche assays show that a single real-time quantitative PCR assay is fully adequate for clinical and therapeutic management of HCV...
  12. ncbi [Serum markers of non-invasive fibrosis in chronic hepatitis C virus infection]
    P Halfon
    Laboratoire de virologie Alphabio, 23, rue de Friedland, 13006 Marseille, France
    Rev Med Interne 27:751-61. 2006
    ..However, these scores must be used only after a validation in multicentric independent studies. The future is based on the comparison and validation of these scores after laboratory methods standardization...
  13. ncbi Chronic Chlamydia pneumoniae infection in patients with symptomatic atherothrombosis
    P Halfon
    Virological Department, Alphabio Laboratory, 23 Rue de Friedland, 13006 Marseille, France
    J Infect 53:93-7. 2006
    ..The aim of the present study was to search for an association between chronic Chlamydia pneumoniae infection, indicated by elevated antibody titers against the pathogen, atherothrombosis and the occurrence of arterial ischemic events...
  14. ncbi Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection
    Philippe Halfon
    Alphabio Laboratory, Marseille, France
    J Med Virol 78:208-15. 2006
    ..All assays, however, failed to detect HCV RNA in some cases. Despite the use of the IU standard HCV-infected patients might be monitored with only one assay...
  15. ncbi Medically assisted procreation and transmission of hepatitis C virus: absence of HCV RNA in purified sperm fraction in HIV co-infected patients
    Philippe Halfon
    Laboratoire Alphabio, Marseille, France
    AIDS 20:241-6. 2006
    ....
  16. ncbi [ANRS-fibrovic and homavic: role of non invasive markers of liver fibrosis and insulin resistance during antiviral treatment in HIV-HCV co-infected patients from ANRS HC 02 RIVABIC trial]
    P Halfon
    Laboratoire de virologie Alphabio, Service de Maladies Infectieuses, Hopital Ambroise Pare, Marseille, France
    Gastroenterol Clin Biol 33:S113-7. 2009
    ..Improving insulin sensitivity may be a useful adjunct to HCV therapy in HIV-HCV co-infected patients...
  17. ncbi Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02
    Philippe Halfon
    Laboratoire Alphabio, Service de Maladies Infectieuses, Hopital Ambroise Pare, Marseille, France
    Antivir Ther 14:211-9. 2009
    ..Here, we aimed to assess the effect of antiviral treatment on non-invasive serological markers of liver fibrosis in HIV-HCV-coinfected patients...
  18. ncbi A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus
    Philippe Halfon
    Laboratoire Alphabio, Hopital Ambroise Pare, France
    Eur J Gastroenterol Hepatol 23:931-5. 2011
    ..The aim of this study was to determine whether a single IL-28B genotype SNP rs8099917 or rs12979860 determination is sufficient to predict treatment failure in patients with chronic HCV...
  19. ncbi Hepatitis C virus resistance to protease inhibitors
    Philippe Halfon
    Virological Departement Laboratoire Alphabio, Hopital Ambroise Pare, Marseille, France
    J Hepatol 55:192-206. 2011
    ....
  20. ncbi Molecular evidence of male-to-female sexual transmission of hepatitis C virus after vaginal and anal intercourse
    P Halfon
    Departement de Virologie, Laboratoire Alphabio, 23 Rue de Friedland, Hopital Ambroise Pare, 13006 Marseille, France
    J Clin Microbiol 39:1204-6. 2001
    ..Based on HVR1 and phylogenetic tree analysis, the couple had closely related isolates. These findings confirm sexual transmission of HCV without other risk factors...
  21. ncbi Hepatitis C virus genotyping based on 5' noncoding sequence analysis (Trugene)
    P Halfon
    Departement de Virologie, Laboratoire Alphabio, 23 Rue de Friedland, Hopital Ambroise Pare, 13006, Marseille, France
    J Clin Microbiol 39:1771-3. 2001
    ..The Trugene and InnoLiPA assays gave concordant results within HCV types in 100% of cases. The ability to discriminate at the subtype level was 76 and 74% for the Trugene and the InnoLiPA assays, respectively...
  22. ncbi Algorithm based on CMV kinetics DNA viral load for preemptive therapy initiation after hematopoietic cell transplantation
    Philippe Halfon
    Laboratoire Alphabio, Hopital Ambroise Pare, Marseille, France
    J Med Virol 83:490-5. 2011
    ..001). A standardized real-time PCR assay is more appropriate than the antigen assay for detecting CMV. It allowed earlier diagnosis of active CMV infection and monitoring of the response to anti-CMV treatment...
  23. ncbi Use of phylogenetic analysis of hepatitis C virus (HCV) hypervariable region 1 sequences to trace an outbreak of HCV in an autodialysis unit
    Philippe Halfon
    Departement de Virologie, Laboratoire de Biologie Medicale Alphabio, Hopital Ambrosie Pare, Marseille, France
    J Clin Microbiol 40:1541-5. 2002
    ..Molecular and epidemiological analysis suggested that nosocomial patient-to-patient transmission was the most likely explanation for the virus spread in the autodialysis unit under study...
  24. ncbi Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy
    Philippe Halfon
    Hopital Ambroise Pare, Marseille, France
    Cancer Biomark 7:133-9. 2010
    ..The detection of high-risk human papillomavirus (HPV) DNA provides higher sensitivity but lower specificity than cytology for the identification of high-grade cervical intraepithelial neoplasia (CIN)...
  25. ncbi Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy)
    Philippe Halfon
    Alphabio Laboratory, Ambroise Pare Hospital, Marseille, France
    J Med Virol 82:2027-31. 2010
    ..Among non-selected consecutive non-responder patients, re-treatment with PEG IFN-α-2a + RIBA is associated with virological response regardless of the presence of antibody-mediated resistance to conventional IFN treatment...
  26. ncbi Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck HPV-screening assay
    Philippe Halfon
    Hopital Ambroise Pare, Marseille, France
    J Clin Virol 47:38-42. 2010
    ..DNA-chip technology, Papillocheck HPV-screening (Greiner) and reverse dot blot, Linear Array (LA) (Roche) are tools to assess the distribution of HPV genotypes...
  27. ncbi Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection
    Philippe Halfon
    Hopital Ambroise Pare, Marseille, France
    J Clin Virol 48:246-50. 2010
    ..The assay can differentiate between the infection by HPV 16, HPV 18 and non-HPV 16/18 types through the distinct fluorescent labels on the type specific probes...
  28. ncbi Semen may harbor HIV despite effective HAART: another piece in the puzzle
    Philippe Halfon
    Department of Virology, Laboratoire Alphabio, Marseille, France
    PLoS ONE 5:e10569. 2010
    ..The risk of male-to-female intravaginal HIV-1 transmission is estimated at about 1 event per 200-2000 coital acts. The aim of this study was to assess the residual risk of HIV presence in semen in patients under HAART therapy...
  29. ncbi Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay
    Philippe Halfon
    Laboratoire Alphabio, Marseille, France
    J Clin Virol 47:177-81. 2010
    ..A recent tool, NucliSENS EasyQ HPV, uses a new concept to directly detect the expression of HPV oncogenic factors (E6 and E7) from the most prevalent HPV genotypes in cervical cancer (16, 18, 31, 33 and 45)...
  30. ncbi [Hepatitis B virus genotypes: clinical, epidemiological and therapeutic implications]
    Philippe Halfon
    , Laboratoire Alphabio, Marseille
    Gastroenterol Clin Biol 26:1005-12. 2002
  31. ncbi Virus-Associated Hemophagocytic Syndrome related to acute CMV and HBV sexual co-infection: a case report
    Philippe Halfon
    Internal Medecine and Infectious Diseases Department, Hopital Ambroise Pare, Marseille, France
    J Clin Virol 46:189-91. 2009
    ..CMV and hepatitis B virus (HBV) can be sexually transmitted. However, co-infection with these viruses has never been reported and the clinical follow-up after acute HBV-CMV infection is not known...
  32. ncbi Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients
    M Bourliere
    Département d Hépato Gastroentérologie, Hopital Saint Joseph, Marseille, France
    Aliment Pharmacol Ther 28:458-67. 2008
    ..Non-invasive liver fibrosis scores such as Hepascore (HS) have been proposed as an alternative to liver biopsy in hepatitis C virus (HCV)-infected patients...
  33. ncbi Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status
    P Halfon
    Alphabio Laboratory, Marseille, France
    J Viral Hepat 13:329-35. 2006
    ..Genotype A was associated with HBeAg positivity and genotype D with HBe antibody positivity. In our European patients, we find no clear association between a given HBV genotype and liver disease severity...
  34. ncbi Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies
    M Bourliere
    Department of Hepato-Gastroenterology, Saint-Joseph Hospital, Marseille, France
    J Viral Hepat 13:659-70. 2006
    ..The combination of all tests without liver biopsy allowed 191/235 (81.3%) patients to be correctly classified; liver biopsy remained mandatory in some patients (18.7%)...
  35. ncbi Integrity of the NS5A (amino acid 2209 to 2248) region in hepatitis C virus 1b patients non-responsive to interferon therapy
    P Halfon
    Laboratoire Alphabio, Hopital de la Conception, Marseilles, France
    Liver 20:381-6. 2000
    ..We tested the hypothesis that absence of mutations in the NS5A (aa 2209-2248) sequence is required for interferon resistance. We also investigated the importance of different HCV-1b isolates in interferon response in France...
  36. ncbi Assessment of spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by two standardized quantitation methods: branched DNA and Amplicor Monitor
    P Halfon
    Alphabio Laboratory, Department of Biochemistry, Hopital de la Conception, Marseille, France
    J Clin Microbiol 36:2073-5. 1998
    ..9- to 5.6-fold with Monitor. These large spontaneous fluctuations (up to 0.75 log), observed daily, weekly, and monthly, raise doubt about the clinical value of a single assessment of pretherapeutic viremia...
  37. ncbi Serological response to infection with different isolates of hepatitis C virus
    P Halfon
    Alphabio Laboratory, Hopital Ambroise Pare, Marseille, France
    J Viral Hepat 9:438-42. 2002
    ..These results demonstrate that using a single test is adequate in the routine diagnosis of HCV infection in clinical laboratory, as recommended by the last French and European consensus conference...
  38. ncbi Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study
    Philippe Halfon
    Department of Virology, Alphabio Laboratory, 23 Street of Friedland, 13006 Marseille, France
    Am J Gastroenterol 101:547-55. 2006
    ..CONCLUSIONS: This prospective independent and multicenter study confirms the diagnostic value of FT and AT found in the princeps study and suggests that FT and AT can be an alternative to biopsy in most patients with chronic HCV...
  39. ncbi Covert transmission of hepatitis C virus during bloody fisticuffs
    M Bourliere
    Department of Hepatogastroenterology, Hopital Saint Joseph, Marseille, France
    Gastroenterology 119:507-11. 2000
    ..This example of transmission could have a major impact in sports such as boxing or rugby. We suggest that in any fight, single use or nondisposable material should be used to dry blood to avoid such contamination...
  40. ncbi [Nucleoside analogues resistance in the treatment of chronic hepatitis B virus infection]
    P Halfon
    , Laboratoire Alphabio, Marseille, France
    Rev Med Interne 24:786-93. 2003
    ..PERSPECTIVES: Treatment of chronic HBV infection, as most of other chronic viral infection, should be based on combination therapy with a special search for the appearance of HBV mutant resistant...
  41. ncbi Outcome of ICSI in HIV-1-infected women
    P Terriou
    Institut de Medecine de la Reproduction, Marseille, France
    Hum Reprod 20:2838-43. 2005
    ..Since several previous reports have indicated that HIV infection may be associated with a decrease in spontaneous fertility, our goal was also to assess the fertility status of the HIV-1-infected women entering our ICSI programme...
  42. ncbi [The diagnostic tools of hepatitis C virus infections]
    Philippe Halfon
    Departement de Virologie, Laboratoire Alphabio, Marseille
    Presse Med 33:538-41. 2004
    ..The latter is useful in selecting the right therapy and duration of treatment, because the response depends on the genotype (better response rate for the genotypes 2 and 3)...
  43. ncbi Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases
    Rene Gerolami
    Service d Hepato Gastroenterologie, Centre Hospitalier Universitaire Conception, Marseille, France
    Antivir Ther 11:1103-6. 2006
    ..Moreover, they highlight that HBV sequence analysis is an essential tool to optimize therapeutic management of HBV chronic infection in clinical practice in order to choose the appropriate nucleos(t)ide analogues...
  44. ncbi Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1
    Françoise Gondois-Rey
    Institut National de la Santé et de la Recherche MédicaleUMR891, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    PLoS ONE 4:e4319. 2009
    ..This finding is important for our understanding of HCV-DC interaction and immunopathogenesis of HCV infection...
  45. ncbi CpG methylation controls reactivation of HIV from latency
    Jana Blazkova
    Institut National de la Sante et de la Recherche Medicale INSERM, UMR891, Centre de Recherche en Cancérologie de Marseille and Institut Paoli Calmettes, Marseille, France
    PLoS Pathog 5:e1000554. 2009
    ..Tight but incomplete control of HIV-1 latency by CpG methylation might have important implications for strategies aimed at eradicating HIV-1 infection...
  46. ncbi A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions
    Jerome Deval
    CNRS and Universités d Aix Marseille I et II, UMR 6098, Architecture et Fonction des Macromolecules Biologiques, Ecole Supérieure d Ingénieurs de Luminy Case 925, Marseille, France
    J Biol Chem 279:25489-96. 2004
    ..Processivity of DNA synthesis remains unaffected. These results explain why the two mutations do not combine in the clinic and might give a mechanism for a decreased viral fitness at the molecular level...
  47. ncbi Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations
    Jerome Courcambeck
    Geoscience, Marseille, France
    Antivir Ther 11:847-55. 2006
    ..We focused on protease mutations conferring HCV resistance to BILN-2061 and described for the first time such mechanism at a molecular level...
  48. ncbi Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations
    Alain Lafeuillade
    Department of Infectious Diseases, General Hospital, Toulon, France
    HIV Clin Trials 3:27-35. 2002
    ..To study the presence of three HIV-1 protease inhibitors (PIs) in the cerebrospinal fluid (CSF), semen, and lymph nodes and to assess the correlations with residual viral replication in these compartments...
  49. ncbi Lymph node enlargement within the hepatoduodenal ligament in patients with chronic hepatitis C reflects the immunological cellular response of the host
    Pierre Muller
    , , , France
    J Hepatol 39:807-13. 2003
    ....
  50. ncbi Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum
    Pascale Trimoulet
    Laboratoire de Virologie, Centre Hospitalier Régional et Université Victor Segalen, CHU de Bordeaux, Bordeaux, France
    J Clin Microbiol 40:2031-6. 2002
    ..03 to 0.14. The bDNA 3.0 assay results were positively correlated with the bDNA 2.0 assay results (r = 0.9533). Taking in account the overall performance, this assay could be used as a routine tool for the HCV RNA quantification...
  51. ncbi Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions
    Philippe Halfon
    Laboratoire Alphabio, Marseilles, Belgium
    AIDS 17:1351-61. 2003
    ..The viral load increase in most patients is compatible with the outgrowth of virus with fewer or no mutations...
  52. ncbi Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France
    Christine Chiaverini
    Department of Dermatology, Archet 2 Hospital, Nice, France
    Dermatology 206:212-6. 2003
    ..To evaluate the role of genetic factors in the pathogenesis of porphyria cutanea tarda (PCT) and their association with chronic hepatitis C...
  53. ncbi Threshold for neutropenia in the adjustment of interferon treatment in HCV infection
    Christophe Renou
    Hepatology 37:949-50; author reply 950. 2003
  54. ncbi Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients
    Caroline Solas
    Laboratory of Pharmacokinetics, University Hospital, Marseilles, France
    Antimicrob Agents Chemother 47:238-43. 2003
    ..Further studies are required to clarify the role and clinical relevance of drug penetration in sanctuaries in terms of long-term efficacy and drug resistance...
  55. ncbi [Treatment of chronic hepatitis C in special groups]
    Marc Bourliere
    Service d Hepato Gastroenterologie, Fondation Hopital Saint Joseph, Marseille
    Gastroenterol Clin Biol 26:B238-47. 2002
  56. ncbi How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited
    Jerome Lambert
    Université Pierre et Marie Curie Paris INSERM, UMR S 707 unité de santé publique, Assistance Publique Hopitaux de Paris, Hopital Saint Antoine, Paris, France
    Clin Chem 54:1372-8. 2008
    ..We explored other fibrosis staging accuracy measures designed for ordinal gold standards, the C-statistic and the Obuchowski measure...
  57. ncbi The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study
    Vincent Leroy
    Department of Hepatogastroenterology, Grenoble, France
    Eur J Gastroenterol Hepatol 14:485-9. 2002
    ..65, P < 0.0001), weight < 75 kg (OR = 1.99, P < 0.035), and age < 50 years (OR = 1.58, P < 0.082). Our results suggest that viral load seems to negatively influence the response to HBV vaccine...
  58. ncbi Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    J Hepatol 48:765-73. 2008
    ..To compare non-invasive biological liver fibrosis scores, as alternatives to liver biopsy, in HIV/HCV co-infected patients...
  59. ncbi Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U707, France
    Clin Infect Dis 46:768-74. 2008
    ..We determined the prevalence and determinants of worsening fibrosis in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who were receiving anti-HCV therapy...
  60. ncbi Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages
    Thierry Poynard
    Assistance Publique Hôpitaux de Paris Groupe Hospitalier Pitié Salpêtrière, Paris, France
    Clin Chem 53:1615-22. 2007
    ..The aim of this study was to assess the relationships between the AUC and the prevalence of each fibrosis stage and to elaborate simple methods of standardization...
  61. ncbi External validation of FibroIndex
    Philippe Halfon
    Hepatology 46:280-1; author reply 281-2. 2007
  62. ncbi Interstitial pneumonia recurrence during chronic hepatitis C treatment
    Christophe Renou
    Am J Gastroenterol 100:1625-6. 2005
  63. ncbi Analytical variability of the Fibrotest proteins
    Maria Alessandra Rosenthal-Allieri
    Laboratoire central d immunologie, CHU de Nice, hôpital de l Archet 1, Rte de St Antoine de Ginestiere, Nice, France
    Clin Biochem 38:473-8. 2005
    ..e. haptoglobin, apolipoprotein A1 and alpha2 macroglobulin. The aim of this study was to evaluate the analytical variability of the FT proteins...
  64. ncbi Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study
    Syria Laperche
    Centre National de Référence pour les Hépatites B et C en Transfusion, Département des Agents Transmissibles par le Sang, Institut National de la Transfusion Sanguine, Paris, France
    J Clin Microbiol 44:3600-7. 2006
    ..Furthermore, the clinical implications of HBV genotyping and the determination of precore/core mutants need to be clearly stated to justify the standardization of these methods...
  65. ncbi Hepatitis B virus genotypes and extrahepatic manifestations
    Patrice Cacoub
    Department of Internal Medicine, hôpital La Pitié Salpêtrière, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    J Hepatol 43:764-70. 2005
    ..This study aimed at correlating the presence of extrahepatic manifestations with hepatitis B virus (HBV) genotypes in patients with chronic HBV infection...
  66. ncbi Long-term persistence of HIV with drug resistance after CD4 cell count-guided structured treatment interruption
    Philippe Halfon
    AIDS 19:1713-4. 2005
  67. ncbi Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis
    Damien Sene
    Department of Internal Medicine, La Pitie Salpetriere Hospital, France
    Clin Biochem 39:715-21. 2006
    ..We assessed the reliability of non-invasive biological scoring indexes (Fibrotest-Actitest [FT-AT], Forns, APRI, age-platelet, platelet, hyaluronic acid) as non-invasive alternatives to liver biopsy (LB) in 138 HCV-infected patients...
  68. ncbi Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience
    Gilles Morali
    Department of Gastroenterology, Shaare Zedek Medical Center, Jerusalem, Israel
    Isr Med Assoc J 9:588-91. 2007
    ..78 and 0.95). The FT-AT was introduced in Israel (Rambam Laboratory) in March 2005...
  69. ncbi Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    J Hepatol 48:35-42. 2008
    ..To analyze the barriers to HCV treatment in HIV-HCV co-infected patients and their evolution between 2004 and 2006...
  70. ncbi Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response
    Dan Avi Landau
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, Paris, France
    Arthritis Rheum 58:604-11. 2008
    ....
  71. ncbi Methylenetetrahydrofolate reductase 677 T allele protects against persistent HBV infection in West Africa
    Jean Pierre Bronowicki
    INSERM U724, Cellular and Molecular Pathology in Nutrition, Faculte de Medecine, University Henri Poincaré of Nancy, Vandoeuvre les Nancy, France
    J Hepatol 48:532-9. 2008
    ..We evaluated the association of determinants of homocysteine metabolism with the outcome of HBV infection...
  72. ncbi Possible zoonotic transmission of hepatitis E from pet pig to its owner
    Christophe Renou
    Centre Hospitalier d Hyères, Hyeres, France
    Emerg Infect Dis 13:1094-6. 2007
    ..We describe possible zoonotic transmission of hepatitis E virus that involved direct contact between a pet pig and its owner...
  73. ncbi Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C
    Maria Alessandra Rosenthal-Allieri
    Laboratoire central d immunologie, CHU de Nice, Hopital de l Archet, Nice Université de Nice Sophia Antipolis, 151 route Saint Antoine de Ginistière, Nice
    Gastroenterol Clin Biol 31:815-21. 2007
    ..The aims of this study were to evaluate the analytical variability of the Fibrotest-Actitest proteins alpha 2-macroglobulin, haptoglobin and apolipoprotein-A1, and to assess their impact on the Fibrotest-Actitest scores...
  74. ncbi [Management of HCV-HIV patients]
    Stanislas Pol
    Unité d Hépatologie, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris
    Gastroenterol Clin Biol 31:4S7-12. 2007
    ..The harmful impact of HIV underlines the need for improving:..
  75. ncbi [Fibrotest limits in Hepatitis C management]
    Philippe Halfon
    Gastroenterol Clin Biol 30:117-20. 2006
  76. ncbi Controversies about the histological features of chronic HCV patients with persistently normal alanine transaminase levels: what can be done about the present definition?
    Christophe Renou
    Gastroenterology 123:1748-9; author reply 1749. 2002
  77. ncbi Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease
    Sophie Hue
    Laboratory of Immunology, Hopital Necker, Paris, France
    J Infect Dis 186:106-9. 2002
    ..HLA class II alleles may weakly contribute to the severity of HCV liver disease. Of persons infected with HCV, only 15%-20% spontaneously clear the virus, and the rest become chronically infected...
  78. ncbi Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy
    Philippe Halfon
    AIDS 22:1694-6. 2008
  79. ncbi Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations
    Jerome Deval
    Architecture et Fonction des Macromolecules Biologiques, UMR 6098 CNRS et Université Aix Marseille I et II, ESIL, Campus de Luminy, 13288 Marseille Cedex 09, France
    J Biol Chem 279:509-16. 2004
    ..All together, these results define at the molecular level how nucleoside-resistant viruses can be driven to reduced viral fitness...